Disease Areas

Due to a viral respiratory infection, post-viral nasal hypersensitivity (PVNH) can occur, resulting in a persistent increase in nasal sensitivity.
Altered sensory signaling within the nasal pathways can persist beyond recovery, affecting perception and neural response patterns.
Subtle residual changes may remain after the infection has resolved, leaving nasal circuits unusually reactive over time.

In some individuals, these changes cause the sensory system to remain highly sensitive even without active infection or blockage.
Sensory pathways may become prone to continuous stimulation signals, leading to irritation or distraction in everyday situations.
This can result in persistent discomfort, even though no congestion or clear pathological trigger can be clinically identified.

Very characteristic of PVNH is the repeated sensation of an imminent sneeze that builds up but never fully resolves.
Episodes are often described as frequent, incomplete reflexes with recurrent activation contributing to mild, cumulative swelling of the nose.
Reflex completion remains inhibited, resulting in irritation and chronic nasal swelling that makes it feel as though the nose is expanding.

A noticeable rise in attention has followed the global COVID-19 pandemic, with more suspected cases discussed in Europe.
Research suggests a temporary dysregulation between nasal mucosa signaling and the neural circuits controlling reflex responses.
Small environmental triggers such as airflow, particles, or temperature shifts may activate pathways without full reflex output.

Current research aims to better understand this emerging sensory condition and its broader neurological implications in patients.
However, the exact underlying mechanisms remain unclear and continue to be explored through ongoing interdisciplinary studies.
Experimental therapies are being developed with our partners to restore normal nasal reflex function and reduce long-term complications.

Want to make a contribution yourself
Nach oben scrollen

Dr. Aanita Weber

Our Founder & Lead Developer
Dr. Aanita Weber, MD, is the founder and lead developer of Nasal Bioactive. In her late twenties, she combines a deep clinical understanding with a passion for translating scientific insight into innovative wellness solutions
After completing her medical degree at Heidelberg University she trained in medicine with a specialization in otolaryngology, Dr. Weber has dedicated her early career to exploring how targeted interventions in the nasal and sinus passages can enhance human health and sensory experience.
Since founding Nasal Bioactive, she has led the development of advanced intranasal formulations and experimental bioactive compounds, combining rigorous clinical methodology with inventive product design. Her work focuses on translating scientific insight into safe, effective, and forward-thinking solutions for everyday wellness.